Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

623.O3.8 Clinical Studies in Lymphoma

Monday, December 8, 2008: 3:30 PM-5:30 PM
120-121-122-123-124-125 - North (Moscone Center)
Moderators:
Gilles Salles and Anton Hagenbeek
3:30 PM
The Impact of the Association of Vinblastine during Induction Chemotherapy and as Maintenance Treatment in Children and Adolescents with High-Risk Anaplastic Large Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

Marie Cecile Le Deley1*, Angelo Rosolen2*, Alfred Reiter, MD3, Denise Williams, MD4*, Keizo Horibe, MD5, Grazyna Wrobel6*, Georg Mann7*, Jozsef Zsiros8*, Anne Uyttebroeck9*, Ildiko Marky10*, Wolfgang Klapper11* and Laurence Brugieres12*

1Biostatistics and Epidemiology, Institute Gustave Roussy, Villejuif, France
2Pediatric Hematology-Oncology, University of Padova, Padova, Italy
3Dept. of Pediatric Hematology and Oncology, Children's University Hospital, Giessen, Germany
4Pediatrics, Addenbrookes Hospital, Cambridge, United Kingdom
5Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
6Pediatric Hematology-Oncology, Wroclaw Medical University, Wroclaw, Poland
7St. Anna Children's Hospital, Vienna, Austria
8Pediatric Hematology-Oncology, AMC, Amsterdam, Netherlands
9University Hospital, Leuven, Belgium
10Pediatrics, Göteborg University, Göteborg, Sweden
11Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany
12Pediatrics and Adolescents, Institute Gustave Roussy, Villejuif, France

3:45 PM
Sequential Evaluation of Outcome in Enteropathy Associated T Cell Lymphoma Comparing Standard Therapeutic Approaches – Surgery or CHOP-Like Chemotherapy with a New High Dose Ifosfamide / Methotrexate and Autologous Stem Cell Transplant Regimen: A Prospective Study of Scotland and Newcastle Lymphoma GroupClinically Relevant Abstract

Michal Sieniawski, MD1, Nithia Angamuthu1*, Kathryn Boyd2*, Richard Chasty3*, John Davies4*, Paul Revell5*, Stephen J Proctor1* and Anne L Lennard6*

1Haematological Sciences, Newcastle University, Newcastle, United Kingdom
2Department of Haematology, Craigavon Area Hospital, Portadown, United Kingdom
3Department of Haematology, University Hospital of North Saffordshire, Stoke on Trent, United Kingdom
4Department of Haematology, Western General Hospital, Edinburgh, United Kingdom
5Staffordshire General Hospital, Stafford, United Kingdom
6Department of Haematology, Royal Victoria Infirmary, Newcastle, United Kingdom

4:00 PM
A Prospective Phase II Trial of An L-Asparaginase Containing Regimen in Patients with Refractory or Relapsing Extra Nodal NK/T-Cell Lymphoma

Arnaud Jaccard1*, Nathalie Gachard2*, Paul Coppo3*, Franck Morschhauser4*, Lionel Galicier5*, Loic Ysebaert6*, Philippe Lenain7*, Bernadette Corront8*, Felipe Suarez9*, Jean Feuillard2*, Philippe Gaulard10*, Dominique Bordessoule1 and Olivier Hermine9*

1Hematologie clinique, CHU, Limoges, France
2Laboratoire d'hématologie, CHU, Limoges, France
3Hematologie clinique, Hôpital Saint-Antoine, Paris, France
4Hematologie clinique, CHU, Lille, France
5Immunologie clinique, Hôpital Saint-Louis, Paris, France
6CHU Purpan, Service d'Hematologie et Inserm U563, Toulouse, France
7Service d'Hématologie, Centre Henri Becquerel, Rouen, France
8Centre hospitalier, Annecy, France
9Hématologie clinique, Hôpital Necker, Paris, France
10Département de Pathologie, Hôpital Henri Mondor, Creteil, France

4:15 PM
Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis

Andres JM Ferreri, MD1, Michele Reni, M.D.2*, Marco Foppoli, M.D.1*, Maurizio Martelli, M.D.3*, Marina Siakantaris, M.D.4*, Maurizio Frezzato, M.D.5*, Maria Giuseppina Cabras, M.D.6*, Alberto Fabbri, M.D.7*, Gaetano Corazzelli, M.D.8*, Fiorella Ilariucci, M.D.9*, Giuseppe Rossi, M.D.10*, Riccardo Soffietti, M.D.11*, Caterina Stelitano, M.D.12*, Daniele Vallisa, M.D.13*, Francesco Zaja, M.D.14*, Marta Gelemur, M.D.15*, Gian Marco Aondio, M.D.16*, Giuseppe Avvisati, M.D.17, Monica Balzarotti, MD18*, Alba Brandes, M.D.19*, Maria Joao Costa, MD20, Henry Gomez, M.D.21*, Attilio Guarini, M.D.22*, Graziella Pinotti, M.D.23*, Luigi Rigacci, M.D.24*, Catrina Uhlmann, M.D.25*, Maria Angelopoulou, M.D.26*, Maria Tirindelli, M.D.27*, Virginia Naso, M.D.28*, Alberto Franzin, M.D.29*, Nicoletta Anzalone, M.D.30*, Maurilio Ponzoni, M.D.1*, Emanuele Zucca, M.D.31*, Federico Caligaris-Cappio, M.D.1* and Franco Cavalli, M.D.32*

1Unit of Lymphoid Malignancies, Department of Oncology, Istituto Scientifico San Raffaele, Milano, Italy
2Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
3Hematology, University La Sapienza, Roma, Italy
4Laikon General Hospital, Athens, Greece
5San Bortolo Hospital, Vicenza, Italy
6Hematology, Hospital Businco, Cagliari, Italy
7Policlinico Le Scotte, Siena, Italy
8Istituto Pascale, Napoli, Italy
9Hematology, AO, Reggio Emilia, Italy
10Department of Hematology, Spedali Civili, Brescia, Italy
11A.O. San Giovanni Battista, Torino, Italy
12Intergruppo Italiano Linfomi, Italy
13Ospedale Civile, Piacenza, Italy
14Clinic of Haematology, Chair of Haematology, University of Udine, Udine, Italy
15GATLA, Grupo Argentino Trataminento de Leucemia Aguda., Buenos Aires, Argentina
16Gravedona, Como, Italy
17Università Campus Bio-Medico di Roma
18Oncology - Hematology, Istituto Clinico Humanitas, Rozzano, Italy
19Busonera Hospital, Padova, Italy
20Lisbon Hospital, Lisbon, Portugal
21Lima Hospital, Lima, Peru
22On the behalf of Intergruppo Italiano Linfomi (IIL), Hematology,, Bari, Italy
23UO Oncologia Medica, Ospedale di Circolo Fondazione Macchi, Varese
24Hematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
25Kantonospital, Aarau, Switzerland
26Hematology, Athens, Greece
27Campus Biomedico, Roma, Italy
28Università La Sapienza, Roma, Italy
29Division of Neurosurgery, Istituto Scientifico San Raffaele, Milano, Italy
30Neuroradiology, Istituto Scientifico San Raffaele, Milano, Italy
31Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
32Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), on behalf of the International Extranodal Lymphoma Study Group, Bellinzona, Switzerland

4:30 PM
RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA

Richard Delarue1*, Corinne Haioun2*, Vincent Ribrag3*, Pauline Brice4*, Alain Delmer5*, Herve Tilly6, Gilles Salles7, Achiel Van Hoof8, Olivier Casasnovas9*, Nicole Brousse1*, Francois Lefrere1* and Olivier Hermine1*

1Hopital Necker, Paris, France
2Hopital Henri Mondor, Creteil, France
3Institut Gustave Roussy, Villejuif, France
4Hopital Saint Louis, Paris, France
5Hopital Robert Debre, Reims, France
6Centre Henri Becquerel, Rouen, France
7Centre Hospitalier Lyon-Sud, Pierre-Benite, France
8A. Z. Sint Jan AV, Brugge, Belgium
9CHU, Dijon, France

4:45 PM
Molecular Remission after Combined Immunochemotherapy Is of Prognostic Relevance in Patients with MCL: Results of the Randomized Intergroup Trials of the European MCL Network

Christiane Pott1*, Eva Hoster2*, Sebastian Böttcher1*, Reiner Siebert3*, Wolfram Klapper4*, Marie Helene Delfau5*, Michael Unterhalt2*, Wolfgang Hiddemann2, Michael Kneba1 and Martin Dreyling2

12nd Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany
2Department of Internal Medicine III, University of Munich-Hospital Großhadern, Munich, Germany
3Department of Human Genetics, University Medical Center Schleswig-Holstein, Kiel, Germany
4Department of Hematopathology, University Medical Center Schleswig-Holstein, Kiel, Germany
5Service d'Immunologie Biologique, Hospital Henri Mondor, Creteil, France

5:00 PM
Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)

Grzegorz S. Nowakowski1, Matthew J. Maurer1*, Thomas M. Habermann2, Stephen M. Ansell1, William R. Macon1*, Kay M. Ristow1*, Cristine Allmer1*, Susan L. Slager1*, Thomas E. Witzig1* and James R Cerhan2

1Mayo Clinic, Rochester, MN
2College of Medicine, Mayo Clinic, Rochester, MN

5:15 PM
The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL

Michael Pfreundschuh, MD, Marita Ziepert*, Marcel Reiser*, Viola Poeschel*, Sibylla Wilhelm*, Tobias Gaska*, Michael Heike*, Norbert Schmitz*, Christian Ruebe*, Markus Loeffler* and Joerg Schubert*

DSHNHL, Homburg, Germany

*signifies non-member of ASH